Analysts predict that Henry Schein, Inc. (NASDAQ:HSIC) will report sales of $2.46 billion for the current quarter, according to Zacks. Eight analysts have made estimates for Henry Schein’s earnings, with the highest sales estimate coming in at $2.51 billion and the lowest estimate coming in at $2.31 billion. Henry Schein reported sales of $3.33 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 26.1%. The company is scheduled to issue its next earnings report on Monday, August 5th.
On average, analysts expect that Henry Schein will report full year sales of $9.93 billion for the current fiscal year, with estimates ranging from $9.30 billion to $10.17 billion. For the next financial year, analysts anticipate that the company will post sales of $10.31 billion, with estimates ranging from $9.70 billion to $10.72 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Henry Schein.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.04. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Henry Schein had a return on equity of 18.35% and a net margin of 4.10%. Henry Schein’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted $0.95 EPS.
Shares of NASDAQ HSIC traded down $0.99 during trading hours on Thursday, reaching $67.67. 1,492,600 shares of the stock traded hands, compared to its average volume of 1,825,600. The stock has a market cap of $10.27 billion, a price-to-earnings ratio of 16.38, a P/E/G ratio of 2.41 and a beta of 0.89. The company has a current ratio of 1.65, a quick ratio of 0.93 and a debt-to-equity ratio of 0.34. Henry Schein has a 52-week low of $56.58 and a 52-week high of $91.35.
In related news, Director Philip A. Laskawy sold 1,084 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $59.86, for a total transaction of $64,888.24. Following the transaction, the director now directly owns 32,899 shares in the company, valued at approximately $1,969,334.14. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.06% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of HSIC. Financial Gravity Companies Inc. bought a new stake in shares of Henry Schein in the 4th quarter worth approximately $29,000. Bruderman Asset Management LLC bought a new stake in shares of Henry Schein in the 4th quarter worth approximately $39,000. CSat Investment Advisory L.P. grew its position in shares of Henry Schein by 115.6% in the 1st quarter. CSat Investment Advisory L.P. now owns 552 shares of the company’s stock worth $33,000 after buying an additional 296 shares during the last quarter. Ipswich Investment Management Co. Inc. bought a new stake in shares of Henry Schein in the 4th quarter worth approximately $45,000. Finally, Parallel Advisors LLC grew its position in shares of Henry Schein by 67.4% in the 1st quarter. Parallel Advisors LLC now owns 586 shares of the company’s stock worth $35,000 after buying an additional 236 shares during the last quarter.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Story: What are no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.